Publications by authors named "Silvia Vitorino"
Introduction: Balloon pulmonary angioplasty (BPA) is an alternative therapy in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or residual/recurrent pulmonary hypertension (PH) after surgery. The aim of this study was to assess the short-term efficacy and safety of a BPA program.
Methods: This prospective single-center study included all BPA sessions performed in CTEPH patients between 2017 and 2019.
Balloon pulmonary angioplasty protocol in a Portuguese pulmonary hypertension expert center.
Rev Port Cardiol (Engl Ed)
September 2021
Article Synopsis
- Balloon pulmonary angioplasty (BPA) is a promising treatment for chronic thromboembolic pulmonary hypertension (CTEPH), especially for patients not suited for surgery or those with ongoing issues post-surgery.
- The document outlines the BPA protocol from a leading center, detailing its approach, including technical aspects, outcome definitions, and patient management before and after the procedure.
- Future research will present the specific results from this protocol, emphasizing its effectiveness as a complementary treatment option for pulmonary hypertension related to chronic pulmonary thromboembolism.
Introduction: Balloon pulmonary angioplasty (BPA) is an alternative therapy in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or residual/recurrent pulmonary hypertension (PH) after surgery. The aim of this study was to assess the short-term efficacy and safety of a BPA program.
Methods: This prospective single-center study included all BPA sessions performed in CTEPH patients between 2017 and 2019.
Objective: To analyze changes in performance indicators five years after Portugal joined the Stent for Life (SFL) initiative.
Methods: National surveys were carried out annually over one-month periods designated as study Time Points between 2011 (Time Zero) and 2016 (Time Five). In this study, 1340 consecutive patients with suspected ST-elevation myocardial infarction (STEMI) who underwent coronary angiography, admitted to 18 24/7 primary percutaneous coronary intervention (PCI) centers, were enrolled.
Introduction: Timely reperfusion with primary percutaneous coronary intervention (PPCI) in ST-segment elevation myocardial infarction (STEMI) improves patient outcomes. In recent years, the Stent for Life (SFL) initiative in Portugal developed an action plan to improve timely access to PPCI. This study aims to evaluate performance indicators in high-risk populations (elderly, female, and diabetic patients).
View Article and Find Full Text PDFIntroduction And Aims: System delay (time between first medical contact and reperfusion therapy) is an indicator of quality of primary percutaneous coronary intervention (pPCI) in ST-segment elevation myocardial infarction (STEMI) patients. This study aimed to assess changes in system delay between 2011 and 2015, and to identify its predictors.
Methods: The study included 838 patients admitted to 18 Portuguese interventional cardiology centers suspected of having STEMI with less than 12 hours' duration who were referred for primary percutaneous coronary intervention.
Introduction And Aims: Shorter patient delays are associated with a better prognosis for patients diagnosed with ST-segment elevation myocardial infarction (STEMI). This study aimed to identify predictors of patient delay in the Portuguese population.
Methods: Data on 994 patients with suspected STEMI of less than 12 hours' duration and referred for primary percutaneous coronary intervention (pPCI) and admitted to 18 Portuguese interventional cardiology centers were collected for a one-month period every year from 2011 to 2015.
Introduction And Aims: The functional significance of coronary lesions can be assessed in the cardiac catheterization laboratory by determination of fractional flow reserve (FFR), thus overcoming one of the major limitations of conventional angiography. The aim of this study was to analyze the long-term clinical course of patients with intermediate coronary stenosis (50-70%) deferred for intervention based on FFR <0.80.
View Article and Find Full Text PDFIntroduction And Objectives: Percutaneous coronary intervention (PCI) with paclitaxel drug-eluting balloons (DEBs) is used mainly for treatment of in-stent restenosis (ISR) and small vessel disease. Our objective was to evaluate the clinical efficacy of this strategy in a multicenter registry.
Methods: Between 2009 and 2010 a prospective registry from two centers enrolled 156 consecutive patients undergoing PCI with at least one DEB.